



Date of original recommendation: 22nd June 2010
Date Re-reviewed: 16th December 2014

Grazax[®] for the treatment of grass pollen induced hayfever in adult patients

The New Therapies Subgroup discussed the above drug at a meeting on 16th December 2014. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG re-considered the use of Grazax[®] for the treatment of grass pollen induced hayfever in adult patients with clinically relevant symptoms and a positive skin-prick test or specific IgE test to grass pollen.

The group does not recommend the use of Grazax[®] for the above indication

Whilst modest clinical benefit has been shown it was not deemed to be cost effective.

Grazax costs £67.50 for 30 tablets and needs to be taken everyday for up to 3 years in adults. The annual cost is therefore around £821 per patient. An annual course of immunotherapy injections costs £320 (excluding admin costs). Symptomatic treatment with loratadine costs £7 and nasal beclometasone around £22.

According to set criteria Grazax[®] was deemed to be a low priority for funding

Review date: September 2017

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.